Thalassemia International Federation

Thalassemia International Federation
Name	Thalassemia International Federation
Type	Non-governmental organization
Founded	1986
Location	Geneva, Switzerland
Focus	Thalassemia, hemoglobinopathies, rare blood disorders

Thalassemia International Federation is an international non-profit organization founded in 1986 that focuses on improving care, prevention, and research for thalassemia and related hemoglobinopathies worldwide. The organization connects clinicians, researchers, patient groups, and policy-makers to address clinical management, public health screening, and advocacy in regions affected by beta thalassemia, alpha thalassemia, sickle cell disease, and other inherited blood disorders. It operates through conferences, guideline development, capacity-building, and collaborations with international health agencies.

History

The federation was established in 1986 following meetings among clinicians and patient advocates from Greece, Italy, Lebanon, India, and United Kingdom who sought coordinated responses after regional programs in Cyprus and Sardinia showed success. Early milestones included participation in workshops alongside representatives from World Health Organization, delegations from United States hematology centers such as Johns Hopkins Hospital and Mayo Clinic, and links with patient organizations from Thailand and Australia. Over subsequent decades the federation convened international symposia drawing speakers from Oxford University, Harvard University, Karolinska Institute, and University of Milan, while issuing consensus statements that influenced screening initiatives in Iran, Turkey, and Spain.

Mission and Objectives

The federation's stated aims include promoting prevention strategies informed by experiences in Cyprus and Sardinia, improving clinical management used at institutions like Great Ormond Street Hospital and Hospital for Sick Children, and supporting research networks similar to collaborations between University College London and Massachusetts General Hospital. Objectives encompass capacity-building akin to programs by Centers for Disease Control and Prevention and UNICEF, advocacy in forums such as World Health Assembly, and dissemination of guidelines comparable to those by European Medicines Agency and American Society of Hematology.

Activities and Programs

Activities include organizing biennial international conferences with participation from delegations representing WHO Regional Office for Europe, Pan American Health Organization, and national ministries from Greece, Cyprus, Italy, India, and Bangladesh. Programs feature training workshops for clinicians from Pakistan and Nigeria, screening campaigns modeled after initiatives in Sardinia and Iran University of Medical Sciences, and patient education drawn from collaborations with Red Cross societies and NGOs such as Save the Children. The federation develops clinical guidelines used alongside protocols from Society for the Study of Inborn Errors of Metabolism and liaises with registries patterned on European Network for Rare Diseases and Global Registry of Hemoglobinopathies.

Governance and Membership

Governance is structured around an elected executive board and advisory committees with members drawn from academic centers including University of Cambridge, Imperial College London, American Society of Hematology, and leading hospitals such as Royal Free Hospital and Hospital de la Santa Creu i Sant Pau. Membership comprises patient organizations, professional societies like International Society of Hematology, and academic units from University of Pennsylvania, Peking University, Aga Khan University, and Monash University. The federation collaborates with national health authorities from Cyprus Ministry of Health, Ministry of Health of Italy, and agencies in Thailand and Malaysia for policy implementation.

Research and Publications

The federation supports multicenter studies and consensus papers involving collaborators from Harvard Medical School, University of Barcelona, Università di Bologna, and National University of Singapore. It publishes clinical guidelines, position statements, and conference proceedings that complement literature in journals such as The Lancet, Blood (journal), British Journal of Haematology, and Haematologica. Research priorities promoted include gene therapy trials influenced by work at University of California, San Francisco and Stanford University, transfusion safety practices from Centers for Disease Control and Prevention, and newborn screening protocols pioneered in United States and Italy.

Funding and Partnerships

Funding and partnerships include grants, charitable donations, and collaborations with organizations such as World Health Organization, European Commission, Bill & Melinda Gates Foundation, and pharmaceutical partners that have supported hemoglobinopathy programs in India, Greece, and Egypt. The federation has engaged in project partnerships with academic consortia at Karolinska Institute and Imperial College London, and with patient coalitions from Lebanon and Cyprus to implement newborn screening, public awareness, and carrier counseling initiatives.

Category:Medical and health organizations Category:Blood disorders